Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies

Authors

Ramaswamy Govindan, Washington University School of Medicine in St. Louis
et al

Journal

British Journal of Cancer

Publication Date

2017

Volume

116

Issue

12

Inclusive Pages

1505-1512

Document Type

Open Access Publication

DOI

10.1038/bjc.2017.92

Rights and Permissions

Rastislav Bahleda, Juneko E Grilley-Olson, Ramaswamy Govindan, Fabrice Barlesi, Laurent Greillier et al. Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. British Journal of Cancer. (2017) 116, 1505–1512. doi:10.1038/bjc.2017.92 www.bjcancer.com Copyright 2017 Cancer Research UK From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ 06 June 2017 This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication

Recommended Citation

Govindan, Ramaswamy and et al, "Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies." British Journal of Cancer. 116, 12. 1505-1512. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/5979